Menu Close

30 years on, are we winning the fight against Alzheimer’s?

UC San Francisco experts say that we have reached a pivotal point in Alzheimer’s disease research, 30 years after the first pharmaceutical came to market. On Jan. 6, 2023, the Food and Drug Administration is expected to give accelerated approval of lecanemab—one of the first drugs to attract widespread enthusiasm among neurologists, after showing positive phase 3 results in slowing the progression of early-stage disease.